References
- World Health Organization. International drug monitoring: the role of the hospital. Geneva, Switzerland: World Health Organization; 1966. Technical Report Series No. 425
- Gianni L, Panzini I, Li S, et al. Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer. Results from international study group trials. Cancer 2006;106:505–513
- Noureddin BN, Seoud M, Bashshur Z, et al. Ocular toxicity in low-dose tamoxifen: a prospective study. Eye 1999;13:729–733
- Salomao SR, Watanabe SES, Berezovsky A, Motono M. Multifocal electroretinography, color discrimination and ocular toxicity in tamoxifen use. Curr Eye Res 2007;32:345–352
- Watanabe SES, Berezovsky A, Motono M, et al. Retinal function in patients treated with tamoxifen. Doc Ophthalmol 2010;120:137–143
- Heier JS, Dragoo RA, Enzenauer RW, Waterhouse WJ. Screening for ocular toxicity in asymptomatic patients treated with tamoxifen. Am J Ophthalmol 1994;117:772–775
- Parkkari M, Paakkala AM, Salminen L, Holli K, Finnish Breast Cancer Group. Ocular side-effects in breast cancer patients treated with tamoxifen and toremifene: a randomized follow-up study. Acta Ophthalmol Scand 2003;81:495–499
- Muftuoglu O, Ucakhan OO, Kanpolat A. Clinical and in vivo confocal microscopy findings in patients receiving tamoxifen citrate. Eye Contact Lens 2006;32:228–232
- Gorin MB, Day R, Constantino JP, et al. Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol 1998;125:493–501
- Longstaff S, Sigurdsson H, O’Keeffe M, et al. A controlled study of the ocular effects of tamoxifen in conventional dosage in the treatment of breast carcinoma. Eur J Cancer Clin Oncol 1989;25:1805–1808
- Tang R, Shields J, Schiffman J, et al. Retinal changes associated with tamoxifen treatment for breast cancer. Eye 1997;1:295–297
- Pavlidis NA, Petris C, Briassoulis E, et al. Clear evidence that long term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients. Cancer 1992;69:2961–2964
- Eisner A, Austin DF, Samples JR. Short wavelength automated perimetry and tamoxifen use. Br J Ophthalmol 2004;88:125–130
- Ashford AR, Donev I, Tiwari RP, Garrett TJ. Reversible ocular toxicity related to tamoxifen therapy. Cancer 1988;61:33–35
- Pugesgaard T, Von Eyben FE. Bilateral optic neuritis evolved during tamoxifen treatment. Cancer 1986;58:383–386
- Colley SM, Elston JS. Tamoxifen optic neuropathy. Clin Exp Ophthalmol 2004;32:105–106
- Beck M, Mills PV. Ocular assessment of patients treated with tamoxifen. Cancer Treat Rep 1979;63:1833–1834
- Verriest G, Van Laethem J, Uvijls A. New assessment of the normal ranges of the FM 100 hue test scores. Am J Ophthalmol 1982;93:635–642
- Evans, DW. Contrast sensitivity testing experts. Available from: http://www.vectorvision.com/html/educationCSV1000Norms.html [last accessed 2 Oct 2013]
- Nayfield SG, Gorin MB. Tamoxifen-associated eye disease. A review. J Clin Oncol 1996;14:1018–1026
- Paganini-Hill A, Clark LJ. Eye problems in breast cancer patients treated with tamoxifen. Breast Cancer Res Treatment 2000;60:167–172
- Zhang JJ, Jacob TJC, Valverde MA, et al. Tamoxifen blocks chloride channels. A possible mechanism for cataract formation. J Clin Invest 1994;94:1690–1697
- Eisner A, O’Malley JP, Incognito LJ, et al. Small optic cup sizes among women using tamoxifen: assessment with scanning laser ophthalmoscopy. Curr Eye Res 2006;31:367–379
- Gualino V, Cohen SY, Delyfer MN, et al. Optical coherence tomography findings in tamoxifen retinopathy. Am J Ophthalmol 2005;140:757–758
- Ritter C, Renner AB, Wachtlin J, et al. Tamoxifen retinopathy: a case series of clinical and functional data. Ophthalmologe 2008;105:544–549
- Eisner A, Luoh SW. Breast cancer medications and vision: effects of treatments for early-stage disease. Curr Eye Res 2011;36:867–885
- Johnson CA. Selective versus nonselective losses in glaucoma. J Glaucoma 1994;3:32–44